Related Experiment Video
Updated: May 22, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Identifying preferred program delivery attributes for long-acting injectable cabotegravir-rilpvirine in three U.S.
Jose I Gutierrez1, Elizabeth T Montgomery2,3, Samantha E Dilworth4
1Department of Family Health Care Nursing, School of Nursing, University of California San Francisco, San Francisco, California, USA.
Background:
Long-acting injectable cabotegravir and rilpivirine (CAB/RPV-LA) may overcome adherence barriers and provide treatment choice among people with HIV (PWH). However, little is known about the factors most likely to facilitate CAB/RPV-LA use.
Methods:
We conducted a discrete choice experiment (DCE) at three urban U.S. HIV clinics, stratified by care engagement status (sub-optimal care engagement defined as most recent HIV RNA ≥200 copies/mL or <2 primary care visits with no HIV RNA measurement in past year). The DCE had 6 attributes: visit location, conversation with one's HIV provider at injection, extra support services, visit length, extended hours, and cost. We used mixed logit regression to estimate preference weights and latent class analysis to identify preference groupings. We examined associations between covariates, attribute preferences and latent class groups, and estimated shares of preference towards hypothetical scenarios.
Results:
Between December 2021 - May 2022, 370 PWH participated. Median age was 46, 34% were cisgender female/gender minority, 59% African American/Black, 13% Latino/a/x, 34% experienced unstable housing, 19% endorsed illicit substance use, and 27% sub-optimal engagement. Cost and visit location were the most important attributes. Latent class analysis identified three groups: 1) cost-conscious (44%), 2) location-driven (34%), and 3) provider/support services-oriented (22%). Sub-optimally engaged PWH preferred extra support services. Shares of preference suggested a predicted use of CAB/RPV-LA exceeding 80% across delivery scenarios with more preferred features.
Conclusion:
Participants strongly preferred CAB/RPV-LA delivery at no cost and accessible at their current HIV clinic. Preferences of PWH with sub-optimal engagement were heterogeneous, suggesting the need for tailored, differentiated delivery programs offering choice.
Related Concept Videos
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Retrovirus Life Cycles

